The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "tofacitinib"

Search results for: tofacitinib

Tofacitinib Promising for Adults with AS

November 24, 2020 • By Michele B. Kaufman, PharmD, BCGP

According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

October 9, 2020 • By Michele B. Kaufman, PharmD, BCGP

Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: FDA, polyarticular juvenile idiopathic arthritis (JIA), Tofacitinib, U.S. Food and Drug Administration (FDA)

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

April 21, 2020 • By Lisa Rapaport

(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: herpes zoster, Rheumatoid Arthritis (RA), shingles, Shingrix, Tofacitinib, vaccine

RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy

July 29, 2019 • By Michele B. Kaufman, PharmD, BCGP

RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: combination therapy, EULAR, Methotrexate, monotherapy, Rheumatoid Arthritis (RA), Tofacitinib

Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes

June 4, 2019 • By Michele B. Kaufman, PharmD, BCGP

In a 24-month clinical trial, tofacitinib proved safe and effective in combination with methotrexate in adult patients with RA…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Methotrexate, Rheumatoid Arthritis (RA), Tofacitinib

Tofacitinib Shows Early Potential for Treating Dermatomyositis

January 16, 2019 • By Carina Stanton

A proof-of-concept study including 10 patients treated for dermatomyositis with tofacitinib, an FDA-approved drug for RA and psoriatic arthritis, shows strong clinical efficacy…... [Read More]

Filed Under: Conditions

Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

October 17, 2017 • By Mary Beth Nierengarten

FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate… [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Spondyloarthritis Tagged With: adalimumab, Ankylosing Spondylitis, Approval, baricitinib, Bimekizumab, biosimilar, drug update, efficacy, FDA, Humira, plaque psoriasis, Psoriasis, Quality, RA, Rheumatoid arthritis, rheumatology, Safety, Tofacitinib

Herpes Zoster & Tofacitinib

October 3, 2017 • By Arthritis & Rheumatology

Shingles, also known as herpes zoster (HZ), is a common and sometimes debilitating disease that disproportionately affects elderly individuals and those who are immunocompromised. Patients with rheumatoid arthritis (RA) have a 1.5–2-fold higher risk of developing HZ compared with healthy adults. Treatment with some disease-modifying anti-rheumatic drugs (DMARDs) has been shown to increase this risk…. [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: herpes zoster, Tofacitinib

Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

September 19, 2017 • By Thomas R. Collins

MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of Rheumatology (EULAR). The findings came in a one-year… [Read More]

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: 2017 EULAR Congress, adalimumab, Annual European Congress of Rheumatology, Clinical, DMARDs, effectiveness, Medication, Methotrexate, ORAL Strategy, outcome, patient care, RA, Research, Rheumatoid arthritis, rheumatology, therapy, Tofacitinib

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

August 29, 2017 • By Reuters Staff

NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report. Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, shingles, Tofacitinib, vaccine, varicella zoster virus

  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.